Teva Pharmaceutical Industries has pushed back its timelines for a US submission for its new three-times-weekly dosing regimen for Copaxone (glatiramer acetate injection), the company revealed, ahead of presenting detailed positive Phase III data for the blockbuster multiple sclerosis drug.
Teva Pharmaceutical Industries has pushed back its timelines for a US submission for its new three-times-weekly dosing regimen for Copaxone (glatiramer acetate injection), the company revealed, ahead of presenting detailed positive Phase III data for the blockbuster multiple sclerosis drug.
The company has already, in June, reported positive top-line results supporting the new dose regime, which if approved, could help...
The regulator has agreed to a six-month preliminary analysis of its pivotal study which could accelerate filing of TSHA-102 for Rett syndrome.
By combining novel drug mechanisms with genetic biomarkers, HMNC Brain Health hopes to transform depression care.
A second pipeline setback within a year for the Finland-based firm has not dented optimism about its growth trajectory.
Larimar reported data from an ongoing open-label study with its protein therapy in FA, showing encouraging skin frataxin levels, but shareholders walked away due to safety worries.
With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.
The PDE4B inhibitor brings a new mechanism of action to the challenging respiratory disease and is the first drug approved for the indication in more than a decade.
The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.
